Goldman Sachs’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,201,089
| Closed | -$75.8M | – | 5886 |
|
|
2020
Q3 | $75.8M | Buy |
2,201,089
+1,889,720
| +607% | +$40.2M | 0.02% | 727 |
|
|
2020
Q2 | $5.2M | Sell |
311,369
-134,799
| -30% | -$2.29M | ﹤0.01% | 2777 |
|
|
2020
Q1 | $6.43M | Buy |
446,168
+142,213
| +47% | +$3.63M | ﹤0.01% | 2440 |
|
|
2019
Q4 | $10.2M | Buy |
303,955
+101,833
| +50% | +$2.85M | ﹤0.01% | 2417 |
|
|
2019
Q3 | $4.23M | Sell |
202,122
-105,622
| -34% | -$2.16M | ﹤0.01% | 2984 |
|
|
2019
Q2 | $6.41M | Sell |
307,744
-17,627
| -5% | -$363K | ﹤0.01% | 2668 |
|
|
2019
Q1 | $7.27M | Buy |
325,371
+135,964
| +72% | +$3.2M | ﹤0.01% | 2687 |
|
|
2018
Q4 | $4.53M | Sell |
189,407
-71,080
| -27% | -$1.84M | ﹤0.01% | 2971 |
|
|
2018
Q3 | $7.11M | Buy |
260,487
+41,716
| +19% | +$1.18M | ﹤0.01% | 2721 |
|
|
2018
Q2 | $5.88M | Buy |
218,771
+30,336
| +16% | +$928K | ﹤0.01% | 2844 |
|
|
2018
Q1 | $6M | Buy |
188,435
+107,557
| +133% | +$3.78M | ﹤0.01% | 2750 |
|
|
2017
Q4 | $3.06M | Sell |
80,878
-166,498
| -67% | -$5.37M | ﹤0.01% | 3424 |
|
|
2017
Q3 | $6.13M | Buy |
247,376
+19,999
| +9% | +$431K | ﹤0.01% | 2967 |
|
|
2017
Q2 | $4.67M | Buy |
227,377
+132,603
| +140% | +$2.53M | ﹤0.01% | 3115 |
|
|
2017
Q1 | $2.06M | Buy |
94,774
+52,558
| +124% | +$1.08M | ﹤0.01% | 3723 |
|
|
2016
Q4 | $863K | Buy |
+42,216
| New | +$863K | ﹤0.01% | 4584 |
|
|
2016
Q2 | – | Sell |
-15,639
| Closed | -$212K | – | 7357 |
|
|
2016
Q1 | $212K | Buy |
+15,639
| New | +$244K | ﹤0.01% | 5565 |
|
|
2015
Q4 | – | Sell |
-15,482
| Closed | -$392K | – | 7457 |
|
|
2015
Q3 | $392K | Buy |
+15,482
| New | +$362K | ﹤0.01% | 5376 |
|
Goldman Sachs's AIMT Position: Q4 2020 in Review
Goldman Sachs sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 2,201,089 shares — an estimated $75.8M sold.
Goldman Sachs first reported a position in AIMT in Q3 2015 and held it in 18 quarters. The position peaked at $75.8M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Goldman Sachs reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Goldman Sachs sold 2,201,089 Aimmune Therapeutics shares in Q4 2020, an estimated $75.8M.
- Goldman Sachs first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 18 quarters.
- Goldman Sachs's Aimmune Therapeutics position peaked at $75.8M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.